EGFR and non-small cell lung carcinoma: In clinical practice, when EGFR-TKI is used to treat NSCLC, the initial tumor shrinks rapidly, indicating that the drug concentration of EGFR-TKI is sufficient, and then there is a long-term SD persistent state.